- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Wagner presents results on ADAC's MCD
At last month's European Association of Nuclear Medicine Congress in Glasgow, Scotland, Dr. Henry Wagner presented preliminary results on the Molecular Coincidence Detection high-energy imaging technique under development by ADAC Laboratories of
At last month's European Association of Nuclear Medicine Congress in Glasgow, Scotland, Dr. Henry Wagner presented preliminary results on the Molecular Coincidence Detection high-energy imaging technique under development by ADAC Laboratories of Milpitas, CA. Wagner, who is a professor of radiation health sciences at John Hopkins Medical Institutions in Baltimore, said MCD could change the way patients with lung cancer are treated.
Wagner is participating in a multicenter clinical trial sponsored by ADAC to demonstrate the clinical effectiveness of MCD in oncology patients whose cancer may have metastasized. ADAC hopes that MCD can help differentiate between benign and malignant nodules, and determine whether surgical treatment is most appropriate.
In Wagner's trials, 35 patients were studied, with MCD producing a 96% sensitivity and an 80% specificity. Results from MCD could enable physicians to identify, prior to surgery, lung cancer patients who have a good chance of surgical cure and those who should be treated instead by radiation or chemotherapy, thus avoiding unnecessary surgery, according to Wagner.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
